Investigational Device Medicare Reimbursement Hinders New Coding
This article was originally published in The Gray Sheet
Executive Summary
Medical device manufacturers seeking a new code for Medicare reimbursement of a new commercial technology likely will have a more difficult time if they received payments for the device during clinical trials from the Health Care Financing Administration, observed Thomas Ault, a principal in the Washington, D.C.-based Health Policy Alternatives, Inc.